Scarica l'app Stockscreener
20.11
4.74%
0.91
Dopo l'orario di chiusura:
19.85
-0.26
-1.29%
Urogen Pharma Ltd Borsa (URGN) Ultime notizie
Insider Sell: Mark Schoenberg Sells 10,000 Shares of UroGen Pharma Ltd (URGN) - GuruFocus
UroGen Pharma CMO Schoenberg sells $176k in shares - Investing.com
UroGen Pharma Ltd. (NASDAQ:URGN) Q2 2025 Earnings Call Transcript - Insider Monkey
UroGen Pharma price target lowered to $40 at H.C. Wainwright - Investing.com India
UroGen Pharma price target lowered to $40 at H.C. Wainwright By Investing.com - Investing.com Australia
URGN: HC Wainwright Lowers Price Target to $40.00, Maintains Buy Rating | URGN Stock News - GuruFocus
Can UroGen Pharma Ltd. disrupt its industryFastest Growing Stock Radar - newsyoung.net
The UroGen Pharma Ltd. (NASDAQ:URGN) Second-Quarter Results Are Out And Analysts Have Published New Forecasts - simplywall.st
UroGen Pharma Ltd. (NASDAQ:URGN) Just Released Its Second-Quarter Results And Analysts Are Updating Their Estimates - Yahoo Finance
UroGen Pharma's Q2 2025 Earnings: A Catalyst for Valuation Re-Rating in Uro-Oncology? - AInvest
UroGen Pharma Q2 2025 Earnings Call Transcript - AInvest
UroGen Pharma Ltd. 2025 Q2ResultsEarnings Call Presentation (NASDAQ:URGN) - Seeking Alpha
Oppenheimer Maintains Buy Rating on Urogen Pharma with $31 Price Target - AInvest
UroGen Pharma Reports Q2 2025 Results and Launches ZUSDURI - TipRanks
UroGen Pharma Receives FDA Approval for ZUSDURI for Recurrent Bladder Cancer - MSN
Guggenheim Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Raises Target Price to $32 - 富途牛牛
Guggenheim raises UroGen Pharma stock price target to $32 on Zusduri launch - Investing.com Australia
UroGen Pharma Q2 Earnings Call: FDA Approval, Revenue Growth, and Expanded Sales Force - AInvest
UroGen Pharma Ltd (URGN) Q2 2025 Earnings Call Highlights: FDA Approval and Revenue Growth ... - Yahoo Finance
UroGen Pharma Ltd (URGN) Q2 2025 Earnings Call Highlights: FDA A - GuruFocus
UroGen Pharma Outpaces Forecasts With Revenue And FDA Nod - Finimize
Urogen Pharma Q2 2025 Earnings Call Transcript - MarketBeat
Health Care Stocks Slipped As Big Players Disappointed - Finimize
UroGen Pharma (URGN) Receives Consistent "Buy" Rating from D. Boral Capital | URGN Stock News - GuruFocus
Sector Update: Health Care - MarketScreener
UroGen Pharma Tops Revenue Forecasts With FDA Approval In Tow - Finimize
Earnings call transcript: UroGen Pharma Q2 2025 results show revenue growth - Investing.com
Earnings call transcript: UroGen Pharma Q2 2025 results show revenue growth By Investing.com - Investing.com South Africa
Urogen Pharma Ltd reports results for the quarter ended June 30Earnings Summary - TradingView
Urogen Pharma (URGN) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
UroGen Pharma falls as wider-than-expected Q2 loss overshadows revenue beat - Investing.com
UroGen Pharma earnings missed by $0.22, revenue topped estimates - Investing.com Australia
UroGen Pharma Expands Commercial Portfolio with Launch of ZUSDUR - GuruFocus
Earnings Flash (URGN) UroGen Pharma Posts Q2 Net Loss $1.05 a Share, vs. FactSet Est of $0.83 Loss - MarketScreener
UroGen Pharma Ltd. SEC 10-Q Report - TradingView
Earnings Flash (URGN) UroGen Pharma Ltd. Reports Q2 Revenue $24.2M, vs. FactSet Est of $23.1M - MarketScreener
UroGen Pharma Expands Commercial Portfolio with Launch of - GlobeNewswire
Breakthrough: UroGen's New FDA-Approved Bladder Cancer Drug ZUSDURI Targets $5B Market as Revenue Jumps 11% - Stock Titan
UroGen Pharma (URGN) Q2 Earnings Preview: Expectations and Revis - GuruFocus
UroGen Pharma (URGN) Q2 Earnings Preview: Expectations and Revisions - GuruFocus
UroGen’s Zusduri benefit maintained in NMIBC Phase III study - Yahoo Finance
URGN: D. Boral Capital Maintains Buy Rating and $25 Price Target - GuruFocus
D. Boral Capital Maintains Buy Rating for UroGen Pharma with $25 Price Target - AInvest
UroGen Pharma (URGN) Highlights Promising Long-Term Data for Bla - GuruFocus
URGN: D. Boral Capital Maintains Buy Rating and $25 Price Target | URGN Stock News - GuruFocus
UroGen Pharma (URGN) Highlights Promising Long-Term Data for Bladder Cancer Treatment - GuruFocus
UroGen Pharma: D. Boral Capital maintains Buy, PT raised to $25 from $25. - AInvest
UroGen Announces 24-Month Duration of Response of 72.2% from the Pivotal Phase 3 ENVISION Trial of ZUSDURI, the First and Only FDA-Approved Medicine for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer - GlobeNewswire
UroGen Announces 24-Month Duration of Response of 72.2% - GlobeNewswire
What institutional investors are buying UroGen Pharma Ltd. stockAchieve superior returns through strategic trading - Jammu Links News
How strong is UroGen Pharma Ltd. company’s balance sheetPhenomenal capital gains - Jammu Links News
What is UroGen Pharma Ltd. company’s growth strategyAchieve superior capital gains with smart trades - Jammu Links News
Does UroGen Pharma Ltd. stock perform well during market downturnsInvest confidently with professional advice - Jammu Links News
What are the technical indicators suggesting about UroGen Pharma Ltd.Rapid portfolio appreciation - Jammu Links News
Is UroGen Pharma Ltd. a growth stock or a value stockAchieve consistent profits with expert advice - Jammu Links News
Should I hold or sell UroGen Pharma Ltd. stock in 2025Unlock exclusive stock market forecasts - Jammu Links News
What markets is FTAIN expanding into Is UroGen Pharma Ltd. stock a good long term investment optionDouble or triple returns - Jammu Links News
What catalysts could drive UroGen Pharma Ltd. stock higher in 2025Build wealth steadily with proven investment techniques - Jammu Links News
1.67%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):